
Cerus (CERS) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
52.4M
Gross Profit
29.0M
55.25%
Operating Income
-3.4M
-6.53%
Net Income
-5.7M
-10.90%
EPS (Diluted)
$-0.03
Balance Sheet Metrics
Total Assets
206.8M
Total Liabilities
150.5M
Shareholders Equity
56.2M
Debt to Equity
2.68
Cash Flow Metrics
Operating Cash Flow
3.4M
Free Cash Flow
-956.0K
Revenue & Profitability Trend
Cerus Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 180.3M | 156.4M | 162.0M | 130.9M | 91.9M |
Cost of Goods Sold | 80.7M | 70.0M | 75.0M | 63.5M | 41.2M |
Gross Profit | 99.5M | 86.4M | 87.1M | 67.4M | 50.8M |
Gross Margin % | 55.2% | 55.3% | 53.7% | 51.5% | 55.2% |
Operating Expenses | |||||
Research & Development | 58.9M | 67.6M | 64.1M | 63.7M | 64.4M |
Selling, General & Administrative | 75.9M | 75.5M | 83.3M | 81.3M | 67.0M |
Other Operating Expenses | -21.1M | -30.4M | -26.3M | -28.7M | -22.3M |
Total Operating Expenses | 113.7M | 112.7M | 121.2M | 116.3M | 109.1M |
Operating Income | -14.2M | -26.3M | -34.1M | -48.9M | -58.3M |
Operating Margin % | -7.9% | -16.8% | -21.0% | -37.4% | -63.5% |
Non-Operating Items | |||||
Interest Income | - | - | - | - | - |
Interest Expense | 8.9M | 8.4M | 5.8M | 4.9M | 3.7M |
Other Non-Operating Income | 2.3M | -2.6M | -2.4M | -198.0K | 2.5M |
Pre-tax Income | -20.8M | -37.3M | -42.3M | -54.1M | -59.6M |
Income Tax | 205.0K | 325.0K | 488.0K | 319.0K | 284.0K |
Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Net Income | -21.0M | -37.6M | -42.8M | -54.4M | -59.9M |
Net Margin % | -11.6% | -24.1% | -26.4% | -41.6% | -65.1% |
Key Metrics | |||||
EBITDA | -10.4M | -22.0M | -32.8M | -45.4M | -53.5M |
EPS (Basic) | $-0.11 | $-0.21 | $-0.24 | $-0.32 | $-0.37 |
EPS (Diluted) | $-0.11 | $-0.21 | $-0.24 | $-0.32 | $-0.37 |
Basic Shares Outstanding | 184563000 | 180270000 | 176545000 | 171279000 | 163949000 |
Diluted Shares Outstanding | 184563000 | 180270000 | 176545000 | 171279000 | 163949000 |
Income Statement Trend
Cerus Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 20.3M | 11.6M | 35.6M | 48.8M | 36.6M |
Short-term Investments | 60.2M | 54.2M | 66.6M | 80.6M | 97.0M |
Accounts Receivable | 29.8M | 35.5M | 34.4M | 25.1M | 21.2M |
Inventory | 38.2M | 39.9M | 29.0M | 26.8M | 23.3M |
Other Current Assets | 3.6M | 3.2M | 4.6M | 5.8M | 5.4M |
Total Current Assets | 152.0M | 144.4M | 170.1M | 187.1M | 183.4M |
Non-Current Assets | |||||
Property, Plant & Equipment | 9.9M | 12.1M | 13.9M | 14.3M | 14.5M |
Goodwill | 2.6M | 2.6M | 2.6M | 2.6M | 2.6M |
Intangible Assets | - | - | - | - | - |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 32.0M | 32.6M | 23.2M | 23.9M | 9.7M |
Total Non-Current Assets | 48.9M | 53.3M | 47.9M | 50.4M | 38.0M |
Total Assets | 200.9M | 197.7M | 218.1M | 237.5M | 221.4M |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 21.7M | 23.8M | 33.0M | 35.6M | 24.2M |
Short-term Debt | 21.6M | 22.5M | 58.3M | 16.6M | 10.4M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | - | - | - | - | - |
Total Current Liabilities | 63.6M | 67.5M | 117.1M | 78.6M | 60.0M |
Non-Current Liabilities | |||||
Long-term Debt | 76.5M | 73.5M | 29.0M | 71.0M | 56.5M |
Deferred Tax Liabilities | - | - | - | - | - |
Other Non-Current Liabilities | 3.9M | 3.2M | 3.5M | 2.3M | 1.2M |
Total Non-Current Liabilities | 80.4M | 76.8M | 32.5M | 73.3M | 57.6M |
Total Liabilities | 144.0M | 144.3M | 149.5M | 151.9M | 117.6M |
Equity | |||||
Common Stock | 186.0K | 181.0K | 177.0K | 174.0K | 168.0K |
Retained Earnings | -1.1B | -1.0B | -1.0B | -964.3M | -910.0M |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 56.9M | 53.4M | 68.6M | 85.6M | 103.8M |
Key Metrics | |||||
Total Debt | 98.1M | 96.0M | 87.2M | 87.6M | 66.9M |
Working Capital | 88.4M | 76.9M | 53.1M | 108.5M | 123.5M |
Balance Sheet Composition
Cerus Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | -21.0M | -37.6M | -42.8M | -54.4M | -59.9M |
Depreciation & Amortization | 1.9M | 2.6M | 3.0M | 3.1M | 3.1M |
Stock-Based Compensation | 22.9M | 20.3M | 24.5M | 23.6M | 18.0M |
Working Capital Changes | 10.5M | -22.0M | -16.0M | -8.8M | -6.8M |
Operating Cash Flow | 17.1M | -34.1M | -29.2M | -34.4M | -43.6M |
Investing Activities | |||||
Capital Expenditures | - | - | - | - | - |
Acquisitions | - | - | - | - | - |
Investment Purchases | -43.0M | -2.5M | -29.6M | -52.1M | -98.8M |
Investment Sales | 37.7M | 15.7M | 40.1M | 65.7M | 50.8M |
Investing Cash Flow | -5.3M | 13.2M | 10.5M | 13.6M | -47.9M |
Financing Activities | |||||
Share Repurchases | - | -175.0K | -104.0K | - | - |
Dividends Paid | - | - | - | - | - |
Debt Issuance | 5.0M | 4.8M | 0 | 15.0M | 0 |
Debt Repayment | -703.0K | - | - | 0 | 0 |
Financing Cash Flow | 3.5M | 9.7M | 108.0K | 24.9M | 80.0M |
Free Cash Flow | 8.5M | -47.8M | -27.6M | -34.8M | -43.4M |
Net Change in Cash | 15.3M | -11.1M | -18.6M | 4.1M | -11.5M |
Cash Flow Trend
Cerus Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-10.82
Forward P/E
-17.71
Price to Book
4.29
Price to Sales
1.23
PEG Ratio
-17.71
Profitability Ratios
Profit Margin
-9.81%
Operating Margin
-6.53%
Return on Equity
-35.56%
Return on Assets
-3.67%
Financial Health
Current Ratio
2.00
Debt to Equity
176.07
Beta
1.55
Per Share Data
EPS (TTM)
$-0.10
Book Value per Share
$0.29
Revenue per Share
$1.03
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
cers | 237.7M | -10.82 | 4.29 | -35.56% | -9.81% | 176.07 |
Abbott Laboratories | 229.3B | 16.53 | 4.53 | 30.93% | 32.43% | 26.50 |
Boston Scientific | 153.7B | 61.76 | 6.85 | 11.55% | 13.55% | 53.09 |
TriSalus Life | 249.8M | 0.09 | -8.67 | 128.34% | -86.61% | -1.73 |
Outset Medical | 237.2M | -0.36 | 1.57 | -87.65% | -82.06% | 63.59 |
Quanterix | 233.7M | -4.91 | 0.67 | -22.41% | -56.05% | 12.15 |
Financial data is updated regularly. All figures are in the company's reporting currency.